CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer

Oncogene

Volumn 36, Issue 15, 2017, Pages 2095-2104

  Zhang, H ^a,b,c   Ye, Y L ^a,b,c   Li, M X ^d   Ye, S B ^a,b,c   Huang, W R ^d   Cai, T T ^a,b,c   He, J ^c   Peng, J Y ^c   Duan, T H ^e   Cui, J ^e   Zhang, X S ^a,b,c   Zhou, F J ^a,b   Wang, R F ^f,g   Li, J ^a,b,c,e  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Colorectal Surgery   (China)

^c Department of Biotherapy ^*  (China)

^d THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD33 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CXCL2 CHEMOKINE; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; SYNAPTOPHYSIN; SYNAPTOTAGMIN I; CXCL2 PROTEIN, HUMAN; ISOMERASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MIF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR RELA;

ADULT; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; BLOOD; CANCER PATIENT; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CHEMOTAXIS ASSAY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN VITRO STUDY; MALE; MIDDLE AGED; MYELOID-DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; BLADDER TUMOR; BONE MARROW CELL; CASE CONTROL STUDY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHEMOKINE CXCL2; CHEMOTAXIS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MYELOID CELLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, INTERLEUKIN-8B; SIALIC ACID BINDING IG-LIKE LECTIN 3; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; URINARY BLADDER NEOPLASMS;

EID: 84990957255     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.367     Document Type: Article

References (48)

1. Vashistha V, Quinn DI, Dorff TB, Daneshmand S. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer 2014; 14: 966.
2. Kaplan AL, Litwin MS, Chamie K. The future of bladder cancer care in the USA. Nat Rev Urol 2014; 11: 59-62.
3. Zhang ZL, Dong P, Li YH, Liu ZW, Yao K, Han H et al. Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients. Chin J Cancer 2014; 33: 165-171.
4. Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer 2014; 2: 14.
5. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Rev Urol 2014; 11: 153-162.
6. Errico A. Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer. Nat Rev Clin Oncol 2015; 12: 63.
7. Becht E, Goc J, Germain C, Giraldo NA, Dieu-Nosjean MC, Sautes-Fridman C et al. Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunol Immunother 2014; 63: 991-997.
8. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 2007; 7: 10.
9. Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 2012; 130: 1109-1119.
10. Huang L, Wu RL, Xu AM. Epithelial-mesenchymal transition in gastric cancer. Am J Transl Res 2015; 7: 2141-2158.
11. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007; 13: 5243-5248.
12. Dubeykovskaya Z, Si Y, Chen X, Worthley DL, Renz BW, Urbanska AM et al. Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer. Nat Commun 2016; 7: 10517.
13. Lin M, Huang J, Shi Y, Xiao Y, Guo T. Influential factors and synergies for radiationgene therapy on cancer. Anal Cell Pathol 2015; 2015: 313145.
14. Gabrilovich D, Nefedova Y. ROR1C regulates differentiation of myeloid-derived suppressor cells. Cancer Cell 2015; 28: 147-149.
15. Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med 2014; 6: 237ra267.
16. Jablonska J, Wu CF, Andzinski L, Leschner S, Weiss S. CXCR2-mediated tumorassociated neutrophil recruitment is regulated by IFN-ß. Int J Cancer 2014; 134: 1346-1358.
17. Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 2007; 252: 86-92.
18. Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Disc 2016; 6: 80-95.
19. Huang JR, Tsai YC, Chang YJ, Wu JC, Hung JT, Lin KH et al. Alphagalactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3. J Immunol 2014; 192: 1972-1981.
20. Mitchell D, Olive C. Regulation of Toll-like receptor-induced chemokine production in murine dendritic cells by mitogen-activated protein kinases. Mol Immunol 2010; 47: 2065-2073.
21. Dubois RN. Role of inflammation and inflammatory mediators in colorectal cancer. Trans Am Clin Climatol Assoc 2014; 125: 358-372.
22. Fang LY, Izumi K, Lai KP, Liang L, Li L, Miyamoto H et al. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res 2013; 73: 5633-5646.
23. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222-225.
24. Mitchell RA, Yaddanapudi K. Stromal-dependent tumor promotion by MIF family members. Cell Signal 2014; 26: 2969-2978.
25. Winner M, Koong AC, Rendon BE, Zundel W, Mitchell RA. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res 2007; 67: 186-193.
26. Scortegagna M, Cataisson C, Martin RJ, Hicklin DJ, Schreiber RD, Yuspa SH et al. HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood 2008; 111: 3343-3354.
27. OuYang LY, Wu XJ, Ye SB, Zhang RX, Li ZL, Liao W et al. Tumor-induced myeloidderived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J Transl Med 2015; 13: 47.
28. De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E et al. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol 2014; 4: 349.
29. Jiang J, Guo W, Liang X. Phenotypes, accumulation, and functions of myeloidderived suppressor cells and associated treatment strategies in cancer patients. Hum Immunol 2014; 75: 1128-1137.
30. Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 2013; 39: 611-621.
31. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer 2014; 2: 31.
32. Chun E, Lavoie S, Michaud M, Gallini CA, Kim J, Soucy G et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep 2015; 12: 244-257.
33. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 2012; 381: 14-22.
34. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G et al. GammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014; 40: 785-800.
35. Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H et al. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/alphaCD40 therapy. J Immunol 2014; 192: 5821-5829.
36. Mao Y, Poschke I, Wennerberg E, Pico de Coana Y, Egyhazi Brage S, Schultz I et al. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 2013; 73: 3877-3887.
37. Yu J, Du W, Yan F, Wang Y, Li H, Cao S et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 2013; 190: 3783-3797.
38. Wang L, Chang EW, Wong SC, Ong SM, Chong DQ, Ling KL. Increased myeloidderived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol 2013; 190: 794-804.
39. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182: 5693-5701.
40. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69: 2514-2522.
41. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014; 211: 781-790.
42. Zhang H, Li ZL, Ye SB, Ouyang LY, Chen YS, He J et al. Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator. Cancer Immunol Immunother 2015; 64: 1587-1599.
43. Shang K, Bai YP, Wang C, Wang Z, Gu HY, Du X et al. Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS One 2012; 7: e51848.
44. Yamamoto M, Kikuchi H, Ohta M, Kawabata T, Hiramatsu Y, Kondo K et al. TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res 2008; 68: 9754-9762.
45. Thummuri D, Jeengar MK, Shrivastava S, Nemani H, Ramavat RN, Chaudhari P et al. Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in vivo model of inflammation by suppressing NF-KB and MAPK signalling. Pharmacol Res 2015; 99: 63-73.
46. Miller LS, O'Connell RM, Gutierrez MA, Pietras EM, Shahangian A, Gross CE et al. MyD88 mediates neutrophil recruitment initiated by IL-1 R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 2006; 24: 79-91.
47. Hong EH, Chang SY, Lee BR, Kim YS, Lee JM, Kang CY et al. Blockade of Myd88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid-derived suppressor cells. Int J Cancer 2013; 132: 2839-2848.
48. Li ZL, Ye SB, OuYang LY, Zhang H, Chen YS, He J et al. COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells. Oncoimmunology 2015; 4: e1044712.